Identification of specifically activated angiogenic molecules in HMGB-1-induced angiogenesis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
High-mobility group box-1 (HMGB-1) is expressed in almost all cells, and its dysregulated expression correlates with inflammatory diseases, ischemia, and cancer. Some of these conditions accompany HMGB-1-mediated abnormal angiogenesis. Thus far, the mechanism of HMGB-1-induced angiogenesis remains largely unknown. In this study, we performed time-dependent DNA microarray analysis of endothelial cells (ECs) after HMGB-1 or VEGF treatment. The pathway analysis of each gene set upregulated by HMGB-1 or VEGF showed that most HMGB-1-induced angiogenic pathways were also activated by VEGF, although the activation time and gene sets belonging to the pathways differed. In addition, HMGB-1 upregulated some VEGFR signaling-related angiogenic factors including EGR1 and, importantly, novel angiogenic factors, such as ABL2, CEACAM1, KIT, and VIPR1, which are reported to independently promote angiogenesis under physiological and pathological conditions. Our findings suggest that HMGB-1 independently induces angiogenesis by activating HMGB-1-specific angiogenic factors and also functions as an accelerator for VEGF-mediated conventional angiogenesis.
Abstract
High-mobility group box-1 (HMGB-1) is expressed in almost all cells, and its dysregulated expression correlates with inflammatory diseases, ischemia, and cancer. Some of these conditions accompany HMGB-1-mediated abnormal angiogenesis. Thus far, the mechanism of HMGB-1-induced angiogenesis remains largely unknown. In this study, we performed time-dependent DNA microarray analysis of endothelial cells (ECs) after HMGB-1 or VEGF treatment. The pathway analysis of each gene set upregulated by HMGB-1 or VEGF showed that most HMGB-1-induced angiogenic pathways were also activated by VEGF, although the activation time and gene sets belonging to the pathways differed. In addition, HMGB-1 upregulated some VEGFR signaling-related angiogenic factors including EGR1 and, importantly, novel angiogenic factors, such as ABL2, CEACAM1, KIT, and VIPR1, which are reported to independently promote angiogenesis under physiological and pathological conditions. Our findings suggest that HMGB-1 independently induces angiogenesis by activating HMGB-1-specific angiogenic factors and also functions as an accelerator for VEGF-mediated conventional angiogenesis.
참고문헌 (34)
- Lotze MT, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal", Nat Rev Immunol, 5, pp.331~342 (2005)
- Shazie Yusein-Myashkova, "Non-histone protein HMGB1 inhibits the repair of damaged DNA by cisplatin in NIH-3T3 murine fibroblasts", BMB Reports, 49(2), pp.99~104 (2016), 생화학분자생물학회
- Tas SW, "Targeting of proangiogenic signalling pathways in chronic inflammation", Nat Rev Rheumatol, 12, pp.111~122 (2016)
- Hori O, "The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system", J Biol Chem, 270, pp.25752~25761 (1995)
- Park JS, "Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein", J Biol Chem, 279, pp.7370~7377 (2004)
- Ivanov S, "A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA", Blood, 110, pp.1970~1981 (2007)
- Yang S, "High-mobility group box-1 and its role in angiogenesis", J Leukoc Biol, 95, pp.563~574 (2014)
- Biscetti F, "Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration", Curr Vasc Pharmacol, 9, pp.677~681 (2011)
- Sims GP, "HMGB1 and RAGE in inflammation and cancer", Annu Rev Immunol, 28, pp.367~388 (2010)
- 정병진, "Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses", BMB Reports, 49(4), pp.214~219 (2016), 생화학분자생물학회
- Tang D, "High-mobility group box 1 and cancer", Biochim Biophys Acta, 1799, pp.131~140 (2010)
- Maeda S, "Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer", Biochem Biophys Res Commun, 360, pp.394~400 (2007)
- Kim SW, "Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion", Neurobiol Dis, 46, pp.147~156 (2012)
- Kang R, "HMGB1 in cancer: good, bad, or both?", Clin Cancer Res, 19, pp.4046~4057 (2013)
- Weidner N, "Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma", N Engl J Med, 324, pp.1~8 (1991)
- Sasahira T, "The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma", Virchows Arch, 450, pp.287~295 (2007)
- van Beijnum JR, "Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature", Blood, 108, pp.2339~2348 (2006)
- Carmeliet P, "Molecular mechanisms and clinical applications of angiogenesis", Nature, 473, pp.298~307 (2011)
- Carmeliet P, "Angiogenesis in cancer and other diseases", Nature, 407, pp.249~257 (2000)
- Jain RK, "Biomarkers of response and resistance to antiangiogenic therapy", Nat Rev Clin Oncol, 6, pp.327~338 (2009)
- Bergers G, "Modes of resistance to anti-angiogenic therapy", Nat Rev Cancer, 8, pp.592~603 (2008)
- Bonapace L, "Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis", Nature, 515, pp.130~133 (2014)
- Cai J, "HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4", Arterioscler Thromb Vasc Biol, 35, pp.2579~2593 (2015)
- Lv B, "High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1", Thromb Haemost, 102, pp.352~359 (2009)
- Liu L, "Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor", Blood, 96, pp.1772~1781 (2000)
- Kojima T, "Proangiogenic role of ephrinB1", EphB1 in basic fibroblast growth factor-induced corneal angiogenesis, 2007, pp.170, 764~773
- Rampon C, "Protocadherin 12 deficiency alters morphogenesis and transcriptional profile of the placenta", Physiol Genomics, 34, pp.193~204 (2008)
- Song G, "Role of VEGF", VEGFR in the pathogenesis of leukemias and as treatment targets (Review)., 2012, pp.28, 1935~1944
- Gerstel D, "CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation", Oncogene, 30, pp.4275~4288 (2011)
- Patruno R, "c-Kit expression, angiogenesis, and grading in canine mast cell", Biomed Res Int, 2014, pp.730246~ (2014)
- Valdehita A, "Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells", Regul Pept, 144, pp.101~108 (2007)
- Tang B, "Vasoactive intestinal peptide receptor-based imaging and treatment of tumors(Review)", Int J Oncol, 44, pp.1023~1031 (2014)
- Ugele B, "Isolation of endothelial cells from human placental microvessels: effect of different proteolytic enzymes on releasing endothelial cells from villous tissue", In Vitro Cell Dev Biol Anim, 37, pp.408~413 (2001)
- Kacemi A, "Culture of endothelial cells from human placental microvessels", Cell Tissue Res, 283, pp.183~190 (1996)